Standout Papers
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease (2016)
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer (2019)
- The PI3K/AKT Pathway as a Target for Cancer Treatment (2015)
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer (2019)
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 (2020)
Immediate Impact
7 by Nobel laureates 9 from Science/Nature 66 standout
Citing Papers
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Deciphering breast cancer: from biology to the clinic
2023 Standout
Works of Ingrid A. Mayer being referenced
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ingrid A. Mayer | 5832 | 3165 | 4896 | 3285 | 207 | 11.6k | |
| Sarat Chandarlapaty | 5812 | 3963 | 6188 | 2878 | 201 | 12.2k | |
| Federico Rojo | 7491 | 3253 | 6966 | 2523 | 263 | 13.2k | |
| Alberto Ocaña | 7114 | 2462 | 3696 | 2453 | 296 | 12.0k | |
| Jungsil Ro | 7720 | 5123 | 3425 | 3610 | 190 | 13.1k | |
| Angelo Di Leo | 9688 | 4372 | 4024 | 5062 | 309 | 14.0k | |
| George Somlo | 5849 | 1703 | 4486 | 3581 | 275 | 11.7k | |
| P. Fumoleau | 9431 | 2609 | 3207 | 4272 | 324 | 14.0k | |
| Joan Albanell | 7586 | 2802 | 4709 | 2674 | 248 | 12.1k | |
| Maurizio Scaltriti | 6154 | 2916 | 5814 | 2042 | 141 | 11.6k | |
| Sara A. Hurvitz | 7870 | 4084 | 3119 | 2491 | 367 | 10.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...